BioMarin Pharmaceutical Inc. - Product Pipeline Review - 2012

Global Markets Direct, May 2012, Pages: 96

BioMarin Pharmaceutical Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “BioMarin Pharmaceutical Inc. - Product Pipeline Review - 2012” provides data on the BioMarin Pharmaceutical Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, BioMarin Pharmaceutical Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from BioMarin Pharmaceutical Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- BioMarin Pharmaceutical Inc. - Brief BioMarin Pharmaceutical Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of BioMarin Pharmaceutical Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of BioMarin Pharmaceutical Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the BioMarin Pharmaceutical Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate BioMarin Pharmaceutical Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of BioMarin Pharmaceutical Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the BioMarin Pharmaceutical Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with BioMarin Pharmaceutical Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of BioMarin Pharmaceutical Inc. and identify potential opportunities in those areas.

Keyword

Current R&D Portfolio of BioMarin Pharmaceutical Inc.; BioMarin Pharmaceutical Inc. - Key Therapeutics; BioMarin Pharmaceutical Inc. - Pipeline Overview and Promising Molecules; BioMarin Pharmaceutical Inc. - News; BioMarin Pharmaceutical Inc. - Latest Updates; BioMarin Pharmaceutical Inc. - Pipeline; BioMarin Pharmaceutical Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
BioMarin Pharmaceutical Inc. Snapshot
BioMarin Pharmaceutical Inc. Overview
Key Information
Key Facts
BioMarin Pharmaceutical Inc. – Research and Development Overview
Key Therapeutic Areas
BioMarin Pharmaceutical Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
BioMarin Pharmaceutical Inc. – Pipeline Products Glance
BioMarin Pharmaceutical Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
BioMarin Pharmaceutical Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
BioMarin Pharmaceutical Inc. – Drug Profiles
BMN 673
Product Description
Mechanism of Action
R&D Progress
BMN-110
Product Description
Mechanism of Action
R&D Progress
BMN-111
Product Description
Mechanism of Action
R&D Progress
BMN-701
Product Description
Mechanism of Action
R&D Progress
Firdapse
Product Description
Mechanism of Action
R&D Progress
PEG-PAL
Product Description
Mechanism of Action
R&D Progress
BioMarin Pharmaceutical Inc. – Pipeline Analysis
BioMarin Pharmaceutical Inc. – Pipeline Products by Therapeutic Class
BioMarin Pharmaceutical Inc. – Pipeline Products By Target
BioMarin Pharmaceutical Inc. – Pipeline Products by Route of Administration
BioMarin Pharmaceutical Inc. – Pipeline Products By Mechanism of Action
BioMarin Pharmaceutical Inc. – Recent Pipeline Updates
BioMarin Pharmaceutical Inc. - Dormant Projects
BioMarin Pharmaceutical Inc. – Company Statement
BioMarin Pharmaceutical Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
BioMarin Pharmaceutical Inc., Recent Developments
BioMarin Pharmaceutical Inc.- Press Release
Mar 08, 2012: BioMarin Completes Enrollment In Phase III Trial For GALNS For Treatment Of Morquio A Syndrome
Feb 16, 2012: BioMarin Initiates Phase I Trial For BMN-111 For Treatment Of Achondroplasia
Jan 03, 2012: BioMarin To Initiate Phase I Trial In BMN-111 For Treatment Of Achondroplasia
Nov 30, 2009: FDA Grants Orphan Drug Designation For 3,4-DAP For Lambert Eaton Myasthenic Syndrome LEMS
Nov 13, 2009: Particles Detected in Vials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme
Nov 13, 2009: Particles Detected in Vials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme
Nov 05, 2009: BioMarin Receives US Patent For Approved Administration Of Kuvan With Food
Nov 05, 2009: United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food
Sep 30, 2009: United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food
Sep 22, 2009: BioMarin Initiates Phase II Clinical Study Of PEG-PAL In PKU
Sep 15, 2009: LEAD Therapeutics Presents New Antibiotic With Potent Activity Against Drug Resistant Bacteria At The 49th ICAAC
Sep 15, 2009: LEAD Therapeutics Presents New Antibiotic With Potent Activity Against Drug Resistant Bacteria At The 49th ICAAC
Aug 19, 2009: BioMarin To Present Kuvan Data At ICIEM Annual Meeting
Aug 19, 2009: Kuvan and Naglazyme Data to Be Presented at the 11th Annual ICIEM Meeting
Jul 30, 2009: BioMarin Receives US Patents Covering Stable Tablet Formulation And Once Daily Dosing Regimen For Kuvan
Jul 13, 2009: Patient Enrollment Completes For Phase I/II Clinical Trial For GALNS For Morquio A Syndrome
Jun 16, 2009: Temporary Production Interruption at Allston Landing Manufacturing Facility Has No Impact on Aldurazyme
Jun 10, 2009: Kuvan Receives Priority Review Status From Health Canada
Jun 09, 2009: Results From Phase 1 Clinical Study Of PEG-PAL In PKU And Update On Phase 2 Clinical Study
May 15, 2009: BioMarin Receives 2009 Corporate Award for the Development of Kuvan
Apr 22, 2009: BioMarin Initiates Phase I/II Clinical Trial For GALNS For Morquio A Syndrome
Mar 30, 2009: BioMarin Receives Notice Of Allowance For Once Daily Dosing Patent For Kuvan
Mar 18, 2009: BioMarin's Clinical Trial Application For GALNS For Morquio A Syndrome Accepted By The MHRA
Feb 03, 2009: BioMarin Pharmaceutical Announces Results From Phase II Clinical Study of 6R-BH4
Feb 03, 2009: Naglazyme Approved by Brazil's National Health Surveillance Agency
Financial Deals Landscape
BioMarin Pharmaceutical Inc., Deals Summary
BioMarin Pharmaceutical Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
BioMarin Pharma Acquires Intellectual Property Of Naglazyme From SA Pathology For $81 Million
BioMarin Pharma To Acquire Biologics Manufacturing Plant In Ireland From Pfizer
BioMarin Pharma Acquires Rights Of SMT C1100 From Summit
BioMarin Re-Acquires Rights To Kuvan From Merck Serono
Partnerships
BioMarin Enters Into An Co-Development Agreement With IGAN Biosciences
BioMarin Enters Into An Agreement With Merck Serono
Licensing Agreements
BioMarin Pharma Enters Into Worldwide Licensing Agreement With Summit
BioMarin Pharma Enters Into Licensing Agreement With Asubio Pharma
BioMarin Enters Into A Licensing Agreement With University of California
AnGes MG Enters Into Licensing Agreement With BioMarin Pharma
Alliant Pharma Enters Into Licensing Agreement BioMarin Pharma
BioMarin Enters Into Licensing Agreement With Daiichi Suntory Pharma
Hi-Tech Pharmacal Enters Into Licensing Agreement With BioMarin Pharma
BioMarin Enters Into Licensing Agreement With Daiichi Suntory Pharma For Phenoptin
Medicis Pharma Enters Into Worldwide Licensing Agreement With BioMarin Pharma
Equity Offering
La Jolla Pharma Completes Private Placement Of Convertible Preferred Stocks For $7.5 million
Summit Completes Private Placement Of $7.1 Million
BioMarin Completes Public Offering Of $134.6 Million
BioMarin Completes Public Offering Of $59.9 Million
Debt Offering
BioMarin Completes Public Offering Of 1.88% Senior Convertible Notes For $324.9 Million
BioMarin Completes Public Offering Of 2.50% Senior Subordinated Convertible Notes For $172.5 Million
Acquisition
BioMarin Pharma Acquires ZyStor Therapeutics
BioMarin Acquires LEAD Therapeutics
BioMarin Pharma Acquires Huxley Pharma From Aceras BioMedical
BioMarin Acquires Ascent Pediatrics From Medicis Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
BioMarin Pharmaceutical Inc., Key Information
BioMarin Pharmaceutical Inc., Key Facts
BioMarin Pharmaceutical Inc. – Pipeline by Indication, 2012
BioMarin Pharmaceutical Inc. – Pipeline by Stage of Development, 2012
BioMarin Pharmaceutical Inc. – Monotherapy Products in Pipeline, 2012
BioMarin Pharmaceutical Inc. – Phase III, 2012
BioMarin Pharmaceutical Inc. – Phase II, 2012
BioMarin Pharmaceutical Inc. – Phase I, 2012
BioMarin Pharmaceutical Inc. – Pipeline By Therapeutic Class, 2012
BioMarin Pharmaceutical Inc. - Pipeline By Target, 2012
BioMarin Pharmaceutical Inc. – Pipeline By Route of Administration, 2012
BioMarin Pharmaceutical Inc. – Pipeline Products By Mechanism of Action, 2012
BioMarin Pharmaceutical Inc. – Recent Pipeline Updates, 2012
BioMarin Pharmaceutical Inc. - Dormant Developmental Projects,2012
BioMarin Pharmaceutical Inc., Other Locations
BioMarin Pharmaceutical Inc., Subsidiaries
BioMarin Pharmaceutical Inc., Deals Summary
BioMarin Pharma Acquires Intellectual Property Of Naglazyme From SA Pathology For $81 Million
BioMarin Pharma To Acquire Biologics Manufacturing Plant In Ireland From Pfizer
BioMarin Pharma Acquires Rights Of SMT C1100 From Summit
BioMarin Re-Acquires Rights To Kuvan From Merck Serono
BioMarin Enters Into An Co-Development Agreement With IGAN Biosciences
BioMarin Enters Into An Agreement With Merck Serono
BioMarin Pharma Enters Into Worldwide Licensing Agreement With Summit
BioMarin Pharma Enters Into Licensing Agreement With Asubio Pharma
BioMarin Enters Into A Licensing Agreement With University of California
AnGes MG Enters Into Licensing Agreement With BioMarin Pharma
Alliant Pharma Enters Into Licensing Agreement BioMarin Pharma
BioMarin Enters Into Licensing Agreement With Daiichi Suntory Pharma
Hi-Tech Pharmacal Enters Into Licensing Agreement With BioMarin Pharma
BioMarin Enters Into Licensing Agreement With Daiichi Suntory Pharma For Phenoptin
Medicis Pharma Enters Into Worldwide Licensing Agreement With BioMarin Pharma
La Jolla Pharma Completes Private Placement Of Convertible Preferred Stocks For $7.5 million
Summit Completes Private Placement Of $7.1 Million
BioMarin Completes Public Offering Of $134.6 Million
BioMarin Completes Public Offering Of $59.9 Million
BioMarin Completes Public Offering Of 1.88% Senior Convertible Notes For $324.9 Million
BioMarin Completes Public Offering Of 2.50% Senior Subordinated Convertible Notes For $172.5 Million
BioMarin Pharma Acquires ZyStor Therapeutics
BioMarin Acquires LEAD Therapeutics
BioMarin Pharma Acquires Huxley Pharma From Aceras BioMedical
BioMarin Acquires Ascent Pediatrics From Medicis Pharma

List of Figures
BioMarin Pharmaceutical Inc. – Pipeline by Indication, 2012
BioMarin Pharmaceutical Inc. – Pipeline by Stage of Development, 2012
BioMarin Pharmaceutical Inc. – Monotherapy Products in Pipeline, 2012
BioMarin Pharmaceutical Inc. – Pipeline By Therapeutic Class, 2012
BioMarin Pharmaceutical Inc. - Pipeline By Target, 2012
BioMarin Pharmaceutical Inc. – Pipeline By Route of Administration, 2012
BioMarin Pharmaceutical Inc. - Pipeline Products By Mechanism of Action, 2012

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• eBay - Strong Execution
• Scientific Games Corporation - Company Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• Ixia - Company Analysis
• SunGard - Profile - US
• Insight into Samsung Electronics' Notebook PC Business Model
• US - Accenture - Company Profile